HEARTBEAM, INC. (BEAT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 11.33M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 5.78M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -20.41M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.33M | (m) | $5.78M | $-20.41M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $12.33M | (m) | $5.25M | $-20.35M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $13.45M | (m) | $5.15M | $-21.14M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $12.98M | (m) | $4.72M | $-20.77M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $12.60M | (m) | $4.34M | $-20.55M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $12.12M | (m) | $4.20M | $-20.61M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $11.05M | (m) | $4.30M | $-19.89M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $10.18M | (m) | $4.49M | $-19.05M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $8.90M | (m) | $4.36M | $-17.72M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $7.54M | (m) | $4.02M | $-15.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $6.80M | (m) | $3.21M | $-15.31M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $6.43M | (m) | $2.37M | $-14.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $6.37M | (m) | $1.79M | $-14.82M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $6.62M | (m) | $1.35M | $-15.04M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $5.68M | (m) | $1.12M | $-13.03M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $4.13M | (m) | $881.00K | $-10.63M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $2.68M | (m) | $583.00K | $-7.47M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $960.00K | (m) | $342.00K | $-4.27M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $255.00K | (m) | $192.00K | $-2.29M | $2.17M | (m) | (m) | -1.06× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $133.00K | (m) | $10.00K | $-788.00K | $280.00K | (m) | (m) | -2.81× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RETRACTABLE TECHNOLOGIES INC (RVP) | United States | $0.021B | -6.44 |
| FEMASYS INC (FEMY) | United States | $0.020B | -1.07 |
| Modular Medical, Inc. (MODD) | United States | $0.018B | -0.88 |
| ACCURAY INC (ARAY) | United States | $0.027B | -0.63 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| SeaStar Medical Holding Corp (ICU) | United States | $0.015B | -1.14 |
| CERENOME, INC. (CNSY) | United States | $0.014B | |
| Sintx Technologies, Inc. (SINT) | United States | $0.012B | -1.10 |
| NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) | United States | $0.012B | |
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |